A Genome-wide analysis of the response to inhaled beta2-agonists in Chronic Obstructive Pulmonary Disease

A Genome-wide analysis of the response to inhaled beta2-agonists in Chronic Obstructive Pulmonary Disease

Short-acting β2-agonist bronchodilators are the most common medications used in treating chronic obstructive pulmonary disease (COPD). Genetic variants determining bronchodilator responsiveness (BDR) in COPD have not been identified.

Bibliographic Details
Main Authors: Hardin, Megan, Cho, Michael H., McDonald, Merry-Lynn, Wan, Emily, Lomas, David A., Coxson, Harvey O., MacNee, William, Vestbo, Jørgen, Yates, Julie C., Agusti, Alvar, Calverley, Peter MA, Celli, Bartolome, Crim, Courtney, Rennard, Stephen, Wouters, Emiel, Bakke, Per, Bhatt, Surya P, Kim, Victor, Ramsdell, Joe, Regan, Elizabeth A., Make, Barry J., Hokanson, John E., Crapo, James D., Beaty, Terri H., Hersh, Craig P.
Format: Online
Language:English
Published: 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848212/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848212/

Similar Items